[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prosthetic-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prosthetic-infection":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100490023","study-of-the-aortic-and-large-arterial-vessel-infections-100490023",false,"NCT05660733","Study of the Aortic and Large Arterial Vessel Infections","French Registry Studying the Characteristics and Prognosis of Aortic and Large Arterial Vessel Infections","Repia","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Aortic or large arterial vessel infection. The diagnosis is made on a number of criteria in favour of the diagnosis (at least 2 of the following 3 criteria):\n\n  * Compatible clinical presentation: local or general inflammatory signs suggestive of a deep infection (fever, chills, scar discharge, fistula, febrile abdominal pain and low back pain, ...) or per-operative finding of an infection in contact with native or prosthetic vascular tissue\n  * And\u002For biological (inflammatory syndrome) and\u002For imaging evidence (infectious sign on native, bioprosthetic or prosthetic vascular tissue on CT and\u002For PET scan) in favour of the diagnosis\n  * And\u002For microbiological evidence (positive serologies, blood cultures or deep samples in favour of infection)\n\nExclusion Criteria:\n\n* Patient who objected to participation in this protocol and data collection\n* Pregnant woman, parturient or breastfeeding mother\n* Person deprived of liberty by a judicial or administrative decision,\n* Person subject to psychiatric care by virtue of articles L.3212-1 and L.3213-1 of the French public health code\n* Person subject to a legal protection measure\n* Person unable to give consent","ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","1 Year","OBSERVATIONAL","Aortic or large arterial vessel infections are rare but serious infections. Their management is based on French and American expert opinions. The quality of evidence supporting these guidelines is low because most publications on the subject correspond to case series and few interventional studies have been performed to validate their management. However, referral centres for vascular surgery are frequently solicited to give their opinion on patients suffering from mycotic aneurysms. In addition, the last few decades have seen the improvement of vascular surgery techniques allowing the management of more and more patients, often elderly and comorbid. There has therefore been an increase in the incidence of infectious complications associated with this care. It is therefore essential to participate in research on aortic and large arterial vessel infections. For this, a monocentric cohort study seems to be an essential first step to better understand the polymorphism and complexity of these patients.",[26,27,28,29],"Aortic Infections and Inflammations","Mycotic Aneurysm","Arterial Infections and Inflammations","Prosthetic Infection","RECRUITING","2025-08-06",{"date":33,"type":34},"2025-08-08","ACTUAL",{"date":36,"type":34},"2023-06-30",{"date":38,"type":21},"2027-01-01",{"name":40,"class":41},"Central Hospital, Nancy, France","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":42},"100558662","soft-tissue-response-to-different-restorative-materials-used-in-implant-dentistry-100558662","NCT06554041","Soft Tissue Response to Different Restorative Materials Used in Implant Dentistry","Inclusion Criteria:\n\n* Participants must be 18 years or older.\n* Participants must be edentulous with at least four missing teeth in the posterior region of the mandible or maxillae.\n* Participants must have appropriate oral hygiene and periodontal status of natural teeth, with a pocket depth of 4mm or less and no bleeding.\n* Dental implants must be fully integrated with no bone resorption or inflammation after three months of implant placement, confirmed by X-ray and clinical examination.\n* Implant placement must be into natural bone without additional procedures such as sinus lift or bone augmentation.\n* The procedure must be a standard implantation with no immediate implant placement.\n* The height of the gingiva must be at least 3mm or more.\n\nExclusion Criteria:\n\n* Patients with systemic diseases such as malignancy, diabetes, osteoporosis, or rheumatoid arthritis.\n* Patients with a history of periodontal treatment.\n* Patients who smoke or use tobacco.\n* Patients who have received antibiotic treatment within three months prior to implantation.\n* Pregnant individuals.",true,{"count":51,"type":21},40,"INTERVENTIONAL",[54],"NA","The goal of this clinical trial is to learn how different materials used in dental implants affect the surrounding gum tissue in adults who need dental implants. The main questions it aims to answer are:\n\nHow do different materials (titanium, PEEK, zirconia, and lithium disilicate) affect inflammation around dental implants? What changes occur in inflammation markers in the gum tissue after 3 and 6 months? Researchers will compare the different materials to see which one causes the least amount of inflammation.\n\nParticipants will:\n\nReceive dental implants made from different materials. Have samples of fluid from around their implants collected for analysis at 3 and 6 months.\n\nUndergo regular dental check-ups to measure gum health, such as bleeding and pocket depth around the implants.",[57,58,59,29,60],"Edentulous Alveolar Ridge","Peri-Implantitis","Peri-implant Mucositis","Prosthetic Complication",[62,63,64,65,66],"Dental Implants","Peri-Implant Soft Tissue","Prosthetic Materials","Inflammation Markers","Oral Health","2024-08-12",{"date":69,"type":34},"2024-08-14",{"date":71,"type":34},"2023-08-23",{"date":73,"type":21},"2026-01-01",{"name":75,"class":41},"Harvard Medical School (HMS and HSDM)",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":52,"phases":86,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":99},"100414123","phase-3-rifabutin-versus-rifampicin-for-treatment-of-staphylococcal-pji-treated-with-dair-100414123","NCT04672525","Rifabutin Versus Rifampicin for Treatment of Staphylococcal PJI Treated With DAIR","Rifabutin Versus Rifampicin for Treatment of Staphylococcal Prosthetic Joint Infection Treated With Debridement, Antibiotics and Implant Retention (DAIR Strategy): a Multicenter Randomized, Open-label, Non-inferiority Trial","RIFAMAB","Inclusion Criteria:\n\n1. Hip or knee Prosthetic joint infection treated by debridement, antibiotic therapy initiation and retention of prothesis (DAIR strategy)\n2. Infected with at least one of the following microorganisms:\n\n   1. Staphylococcus aureus\n   2. Coagulase-negative staphylococci\n3. Microorganisms susceptible to rifampicin and at least one other antibiotic suitable for the treatment of PJI (e.g., penicillin, fluoroquinolone, (doxy\u002Fmino)cycline, oxazolidinone, cotrimoxazole, daptomycin, glycopeptide, macrolide, fusidic acid), regardless of sensitivity to methicillin.\n4. Age ≥ 18 years\n5. At least 2 days of appropriate (i.e., covering pathogen(s) identified in the intraoperative samples) empirical agents are needed. Pre-randomization antimicrobial therapy could be: flucloxacillin, oxacillin, vancomycin, daptomycin. β-lactam plus β-lactamase-inhibitors (e.g. ampicillin+sulbactam, piperacillin+tazobactam), cephalosporins (except ceftazidime), carbapenems, teicoplanin, ceftaroline, ceftobiprole.\n6. Signed Inform consent\n7. Patient having the rights to French social insurance\n8. For women of childbearing potential i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile and excluding oestroprogestative-based contraception, any effective contraceptive: vasectomy (for men), intrauterine device copper, feminine sterilization, condom, sexual abstinence is required. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause\n\nExclusion Criteria:\n\n1. Suspicion of reduce absorption of oral treatment due to abdominal disorder Known or suspected malabsorption (imperfect absorption of food material by the small intestine)\n2. Polymicrobial infection due to other than staphylococcus species susceptible to rifampicin\n3. Known or suspected allergy to rifabutin and\u002For rifampicin\n4. Diagnosis of endocarditis associated to PJI\n5. Renal transplant or Chronic kidney disease with an eGFR of less than 30ml\u002Fmin\u002F1.73m²\n6. Other Solid Organ Transplant\n7. Liver cirrhosis, Child-Pugh score C\n8. Any other concomitant infection which required a prolonged course of intravenous antibiotic therapy\n9. Oestroprogestative-based contraception\n10. Oral anticoagulant drugs\n11. Other drug-drug interaction that contraindicated rifampicin or rifabutin\n12. Porphyria\n13. Unable to take oral treatment\n14. Receive empirical postoperative antibiotic treatment by rifampicin or rifabutin prior to randomization\n15. Pregnancy or lactating women\n16. Curator or guardianship or patient placed under judicial protection\n17. Participation in other interventional research during the study",{"count":85,"type":21},436,[87],"PHASE3","Rifampicin, is key in the treatment of staphylococcal PJIs. Rifabutin has a better profile of tolerance than rifampicin regarding the risk of interaction with concomitant medications and liver disorders. The hypothesis is that rifabutin may be an alternative antibiotic option as efficient as rifampicin for the treatment of staphylococcal PJIs, with a better safety profile. The investigator aim to demonstrate the non-inferiority of rifabutin as compared with rifampicin prescribed in combination treatment for PJIs.",[29],"2022-05-09",{"date":92,"type":34},"2022-05-10",{"date":94,"type":34},"2021-11-08",{"date":96,"type":21},"2027-06",{"name":98,"class":41},"Tourcoing Hospital",30]